XML 85 R69.htm IDEA: XBRL DOCUMENT v3.8.0.1
Subsequent Event - Additional Information (Detail) - Subsequent Event [Member]
Feb. 13, 2018
USD ($)
$ / shares
shares
Purchase Agreement [Member]  
Subsequent Event [Line Items]  
Shares expected to be issued in future period | shares 8,284,600
Sale of stock consideration expected to be received in future period $ 850,000,000
Issued price per share | $ / shares $ 102.60
Subsequent event, description The closings of the BMS Collaboration Agreement and the Purchase Agreement will be simultaneous and are expected to occur during the second quarter of 2018
NKTR-214 [Member] | Nektar's [Member]  
Subsequent Event [Line Items]  
Global commercialization profits and losses sharing percentage 65.00%
NKTR-214 [Member] | Bristol-Myers Squibb [Member]  
Subsequent Event [Line Items]  
Non-refundable upfront payment to be received in cash in future period $ 1,000,000,000
Global commercialization profits and losses sharing percentage 35.00%
NKTR-214 [Member] | Maximum [Member] | Bristol-Myers Squibb [Member]  
Subsequent Event [Line Items]  
Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones $ 1,430,000,000
Eligible additional cash payments receivable upon achievement of certain sales milestones $ 350,000,000